| National Hospital for Neurology and Neurosurgery, Queen Square | |
|---|---|
| Location | London, England, UK |
| Type | Specialist Hospital and Research Center |
| Founded | 1859 |
| Website | https://www.uclh.nhs.uk/ |
| Focus Areas | Alzheimer's Disease, Parkinson's Disease, ALS, Multiple Sclerosis, Epilepsy, Movement Disorders, Dementia |
| Affiliation | UCL Queen Square Institute of Neurology |
The National Hospital for Neurology and Neurosurgery (NHNN) at Queen Square, London, is one of the world's oldest and most prestigious specialist neurological hospitals. Founded in 1859, the hospital has been at the forefront of neurology and neurosurgery for over 160 years, making fundamental contributions to understanding and treating neurological disorders[1]. As part of University College London Hospitals NHS Foundation Trust, the hospital combines world-class clinical care with cutting-edge research, making it a global destination for patients with complex neurological conditions.
Queen Square represents a unique institution where pioneering basic science discoveries have been translated into clinical breakthroughs that have transformed the lives of millions of patients worldwide. The hospital's rich history, combined with its continued commitment to innovation, ensures that it remains at the cutting edge of neurological research and patient care.
The National Hospital for the Paralysed was founded in 1859 by Dr. Charles Elam as a small facility dedicated to treating patients with paralysis and neurological conditions. The hospital moved to its current location in Queen Square in 1866, establishing itself as the world's first specialist neurological hospital. In 1911, the hospital merged with the National Hospital for the Relief and Cure of Paralysis and Epilepsy, expanding its mission to include epilepsy research and treatment.
The early years of Queen Square were marked by several landmark discoveries that would shape the field of neurology:
The first half of the 20th century represented a golden era for Queen Square, with numerous breakthrough discoveries that established modern neurology:
1913: Sir Henry Head, one of the founding figures of modern neurology, established the department of neurological studies at Queen Square, pioneering the study of sensation and neurological examination techniques.
1920s-1930s: Queen Square researchers made fundamental contributions to understanding movement disorders, including early work on Parkinson's disease and the development of neurosurgical approaches to treating movement disorders.
1940s: During World War II, Queen Square became a center for treating head injuries and developing rehabilitation approaches that would influence modern neurorehabilitation.
The post-war period saw continued expansion and innovation at Queen Square:
Today, Queen Square operates as part of the UCLH NHS Foundation Trust, maintaining its position as one of the world's premier neurological institutions while continuing to push the boundaries of what is possible in neurological diagnosis and treatment.
The hospital provides comprehensive diagnostic and treatment services for cognitive disorders[3][4]:
Queen Square's Alzheimer's disease program offers:
Queen Square provides specialized care for:
Queen Square is world-renowned for movement disorders, offering comprehensive services for Parkinson's disease and related conditions[9][10]:
Queen Square hosts one of the UK's leading ALS centers[14][15]:
The MS center provides comprehensive services[16][17]:
Queen Square provides specialized epilepsy services[18]:
Queen Square treats a comprehensive range of neurological conditions:
The Dementia Research Centre at Queen Square conducts cutting-edge research on dementia[4:1][3:1]:
This world-leading imaging center provides state-of-the-art neuroimaging for research[20:1]:
The UCL Queen Square Institute of Neurology (ION) represents a partnership between Queen Square Hospital and UCL that brings together basic and clinical researchers[2:1]:
Queen Square has been home to numerous neurological pioneers:
Sir Charles Sherrington (1857-1952): Nobel laureate who developed fundamental concepts of how neurons communicate and how reflexes work.
Sir Henry Head (1861-1940): Pioneered the systematic study of sensation and neurological examination.
Sir Charles Symonds (1890-1975): Made major contributions to understanding epilepsy and the blood-brain barrier.
Today's Queen Square researchers continue to make important contributions:
Queen Square has made numerous landmark contributions to neurology:
The hospital provides excellent training opportunities:
Queen Square participates in major European research networks:
Queen Square's approach to patient care emphasizes:
The National Hospital for Neurology and Neurosurgery at Queen Square represents a unique institution with a remarkable legacy of innovation in neurology. Over its 160-year history, the hospital has been responsible for fundamental discoveries that have transformed our understanding and treatment of neurological diseases. From the identification of the first neurotransmitter to pioneering deep brain stimulation surgery, Queen Square has consistently pushed the boundaries of what is possible in neurology.
Today, Queen Square continues this tradition through its comprehensive clinical services, cutting-edge research programs, and commitment to training the next generation of neurologists. The integration of basic science with clinical research ensures that discoveries can be rapidly translated into new treatments for patients.
The hospital's future looks bright as it continues to attract world-class researchers and clinicians, invest in state-of-the-art facilities, and pursue innovative approaches to understanding and treating neurological disease. For patients with complex neurological conditions, Queen Square remains a global destination offering hope through access to the latest treatments and the expertise of leading specialists.
As neurological diseases become more common with aging populations, the work of institutions like Queen Square becomes increasingly important. The hospital's commitment to improving the lives of patients with neurological conditions, through both outstanding clinical care and groundbreaking research, ensures that it will continue to play a central role in neurology for years to come. The hospital's strategic location within London provides access to diverse patient populations, while its partnership with UCL facilitates collaboration with leading basic scientists and engineers working on cutting-edge research initiatives.
One of the defining features of Queen Square is its seamless integration of research and patient care. Unlike many institutions where basic science and clinical practice exist in separate worlds, Queen Square has long embraced a model where researchers and clinicians work side by side. This integration accelerates the translation of scientific discoveries into clinical applications, ensuring that patients have access to the latest treatments and diagnostic approaches.
National Hospital for Neurology and Neurosurgery. About Us. ↩︎
Rodriguez RL, et al. Cognitive impairment and dementia: clinical features and management. Nat Rev Neurol. 2023. ↩︎ ↩︎
Schott JM, et al. Alzheimer's disease: biomarkers for early detection. Lancet Neurol. 2023. ↩︎ ↩︎
Mendonca MD, et al. Frontotemporal dementia: clinical features and management. Nat Rev Neurol. 2023. ↩︎
Gordon E, et al. Dementia with Lewy bodies: clinical features and biomarkers. Brain. 2024. ↩︎
Rini V, et al. Vascular cognitive impairment and dementia. Nat Rev Neurol. 2023. ↩︎
Masellis M, et al. Young onset dementia: diagnosis and management. Lancet Neurol. 2023. ↩︎
Foltynie T, et al. Parkinson's disease: current treatment and emerging therapies. Lancet Neurol. 2023. ↩︎
Lees AJ, et al. Parkinson's disease: Lewy body pathology and alpha-synuclein. Nat Rev Neurol. 2023. ↩︎
Warren N, et al. Deep brain stimulation for movement disorders. Brain. 2023. ↩︎
Zrinzo L, et al. Stereotactic neurosurgery for movement disorders. Nat Rev Neurol. 2024. ↩︎
Moss J, et al. Huntington's disease: genetic and molecular mechanisms. Nat Rev Neurol. 2023. ↩︎
Hardiman O, et al. Amyotrophic lateral sclerosis: current concepts and therapeutic advances. Nat Rev Neurol. 2023. ↩︎
Mehta AR, et al. Motor neuron disease: pathophysiology and therapy development. Nat Rev Neurol. 2023. ↩︎
Chao ST, et al. Multiple sclerosis: disease modification and neuroprotection. Nat Rev Neurol. 2023. ↩︎
Bjornevik K, et al. Multiple sclerosis epidemiology and risk factors. Nat Rev Neurol. 2023. ↩︎
Rowan M, et al. Epilepsy and neurodegenerative diseases. Nat Rev Neurol. 2023. ↩︎
London Z, et al. Myasthenia gravis: autoimmune mechanisms and treatment. Nat Rev Neurol. 2023. ↩︎
Rytting HC, et al. Neuroimaging in neurodegenerative diseases. Nat Rev Neurol. 2024. ↩︎ ↩︎